DMAC
DiaMedica Therapeutics Inc. (NASDAQ)
Healthcare — Biotechnology
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Price History
Fundamentals
| Market Cap | $400.89M |
| P/E Ratio (TTM) | - |
| Forward P/E | -8.45 |
| EPS (TTM) | $-0.71 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -86.47% |
| Debt/Equity | 0.45 |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $15.50 |
| Analysts | 4 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 86.0 |
| Beta | 1.00 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $10.42 |
| 52-Week Low | $3.55 |
| 50-Day Avg | $6.09 |
| 200-Day Avg | $7.17 |
| Avg Volume | 202.3K |
| Volume | 123.5K |
Performance Analysis
NEUTRALDMAC presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:06 UTC
Back to Screener Export Report